Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YIA
|
|||
| Former ID |
DIB011712
|
|||
| Drug Name |
CNVN-202
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
| Company |
MD Anderson Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tumor suppressor candidate 2 (TUSC2) | Target Info | Suppressor | [2] |
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.